AFC-TAB-024

antibody from Creative Biolabs

Targeting: ITGAL CD11A, LFA-1

No application information provided.

Antibody Data

Product number

AFC-TAB-024

Provider

Creative Biolabs

Product name

Afuco? Anti-ITGAL ADCC Recombinant Antibody (Efalizumab), ADCC Enhanced

Antibody type

Monoclonal

Description

This product is an ADCC enhanced antibody produced by our Afuco? platform. Recombinant monoclonal antibody to Human CD11A. Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.

Reactivity

Human

Conjugate

Unconjugated

Antibody clone number

Efalizumab

Storage

Store at +4¡ãC short term (1-2 weeks). Aliquot and store at -20¡ãC long term. Avoid repeated freeze/thaw cycles.